How FMedSci was paid
$5.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Paul Peter Tak, M.D., Ph.D., FMedSciChief Executive Officer | $743,592 | $3,916,028 | $396,653 | — | $288,289 | $5,344,561 |
| Francesca Barone, M.D., Ph.D.Chief Scientific Officer | $483,312 | $857,797 | — | $206,427 | $14,000 | $1,561,536 |
| Charles SchochChief Financial Officer | $398,500 | $826,465 | — | $232,320 | $13,532 | $1,470,817 |
What changed and why
- $5.3MCEO total compensation increased to $5,344,561 in fiscal year 2025 due to larger stock and option awards.
- 110%Corporate goals were achieved at 110 percent based on performance metrics established by the compensation committee.
- $721KAnnual base salaries were $721,188 for Dr. Tak and $469,153 for Dr. Barone during fiscal year 2025.
- $440KMr. Schoch received a base salary increase to $440,000 when he became Chief Financial Officer in June 2025.
- Aon Plc d/b/a Radford advised the compensation committee on executive compensation market competitiveness and peer groups.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.